How Wegovy supports cardiovascular health — what the evidence shows

What SELECT actually found, and why it matters beyond weight

Most weight-loss medicines earn their cardiovascular credentials indirectly: if you weigh less, the reasoning goes, your heart works less hard. SELECT challenged that assumption. Participants all had established atherosclerotic cardiovascular disease (prior heart attack, stroke or peripheral arterial disease) and a BMI of 27 or above. Crucially, no one in the trial had type 2 diabetes, which removed a major confounding variable that had complicated earlier GLP-1 cardiovascular studies.

Over a median follow-up of around 33 months, those taking semaglutide 2.4mg saw a 20% relative reduction in the composite endpoint of cardiovascular death, non-fatal heart attack and non-fatal stroke compared with placebo. That absolute difference was roughly 1.5 percentage points across the study population, meaningful at scale when millions of people live with this risk profile. Researchers noted the separation between treatment and placebo curves began early and continued to widen, suggesting mechanisms beyond fat loss were at work. The wider cardiovascular effects of semaglutide are still being studied, but the MHRA and the licence now reflect this evidence directly. The MHRA's regulatory track record with semaglutide demonstrates it scrutinises new indications carefully before granting them.

One practical implication: people who began semaglutide primarily for weight management may be receiving cardiovascular benefit simultaneously. This is one reason our prescribers sometimes describe the medicine's profile as unusually broad for its class.

The mechanisms that researchers think are behind the cardiovascular effect

A question our prescribers hear most weeks is: if weight loss alone explains the heart benefit, why did SELECT show risk reduction so quickly? The short answer is that semaglutide probably acts through several pathways at once.

GLP-1 receptors are expressed not just in the gut and brain, they are also present in cardiac tissue and blood vessel walls. Animal and early human studies point to direct anti-inflammatory effects on arterial plaques, modest reductions in blood pressure, improvements in lipid profiles and a reduction in C-reactive protein (an inflammation marker tightly linked to cardiovascular risk). How Wegovy works across the body is increasingly understood as a systemic hormonal effect, not simply a consequence of eating less.

Reductions in body weight do contribute, less visceral fat means lower mechanical strain on the heart and better metabolic signalling. But the speed and consistency of cardiovascular benefit in SELECT, even in participants who lost relatively little weight, suggests the two effects are at least partly additive. This is one reason the broader health picture for Wegovy has shifted substantially since early weight-management trials. None of this changes the fundamental point: Wegovy is a prescription medicine and whether these mechanisms translate into personal benefit depends entirely on individual clinical factors a prescriber assesses.

Who the cardiovascular licence covers, and what it does not

The UK cardiovascular indication applies to adults with established cardiovascular disease and a BMI of 27 or above. It does not extend to people seeking heart-health protection as a precaution, to those with type 2 diabetes (separate licence pathways apply), or to anyone under 18. The weight-management licence has its own BMI thresholds (30 and above, or 27 and above alongside a weight-related condition) which overlap but are distinct from the cardiovascular criteria.

Wegovy is not suitable during pregnancy, while breastfeeding, or for people trying to conceive, and some women taking it have found that Wegovy stopped their period, which is worth discussing with a prescriber before starting. Anyone with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take it. Pancreatitis history and certain gastrointestinal conditions require careful prescriber assessment. The health considerations around Wegovy cover the contraindication list in more detail. Gastrointestinal side effects (nausea, loose stools, reflux, reduced appetite) are the most common; they tend to ease as the body adjusts, but they can be persistent for some people. A full side-effect profile is in the semaglutide overview.

If you are paying privately, the cost of Wegovy varies by dose and provider; the dose schedule begins at 0.25mg and is titrated by the prescriber. That titration, and the clinical review behind it, is where safety and effectiveness converge. Worth understanding before you start.

Wegovy's cardiovascular evidence in the context of NHS access and private care

On the NHS, Wegovy is available through specialist weight management services under NICE guidance (TA875), not as a standalone cardiovascular treatment. Waiting lists for those services are long in many parts of England, and the cardiovascular indication does not yet open a separate, faster NHS access route for most patients. Scotland, Wales and Northern Ireland operate under their own commissioning arrangements with different thresholds.

For people who meet the eligibility criteria but do not want to wait, a private prescription through a regulated pharmacy is the legal alternative. The full Wegovy overview covers the licence, the dosing schedule and what clinical assessment involves. You can also browse weight-loss treatment options across the medicines we work with if you are still deciding which route makes sense for your situation. Speak to our prescribers for a same-day clinical review, the conversation begins with a free consultation and no obligation to proceed.